Search for: "Anda Inc."
Results 181 - 200
of 961
Sorted by Relevance
|
Sort by Date
11 May 2010, 4:00 pm
IMPAX Laboratories, Inc. [read post]
4 Aug 2013, 9:53 pm
UCB, Inc. et al. v. [read post]
1 Jun 2014, 9:25 am
Cephalon Inc. v. [read post]
24 Aug 2014, 9:42 pm
Aptalis Pharmatech Inc. et al. v. [read post]
17 Nov 2014, 9:59 pm
• Defendants: Pharmadax USA, Inc.; Pharmadax Inc.; Pharmadax (Guangzhou) Inc. [read post]
15 Dec 2020, 12:21 pm
(Proper venue for ANDA filing — what counts as having “has committed acts of infringement”). [read post]
23 Jun 2013, 8:50 pm
• Defendants: Par Pharmaceutical Inc.; Actavis Elizabeth LLC; Actavis Inc. [read post]
26 Oct 2014, 9:17 pm
• Defendants: Pharmadax USA, Inc.; Pharmadax Inc.; Pharmadax Guangzhou Inc. [read post]
5 Jul 2018, 1:37 pm
The company also acquired a portfolio of 25 FDA-approved abbreviated new drug applications and four pipeline ANDAs ... [read post]
18 Oct 2009, 5:42 pm
Teva Pharmaceutical Industries Ltd. issued a press release last week discussing the abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXONE ® (glatiramer acetate injection), filed by Mylan Pharmaceuticals Inc. [read post]
11 Mar 2012, 4:43 pm
FDA’s recent approval of ANDAs for generic versions of Pfizer, Inc. [read post]
31 Jul 2023, 1:51 pm
Background UCB, Inc. [read post]
10 Nov 2020, 8:53 pm
Brands LLC of prior Federal Circuit interpretations that venue was coincident with personal jurisdiction, last Thursday the Federal Circuit arrived at a decision regarding where proper venue does not lie in ANDA litigation, in Valeant Pharmaceuticals North America LLC v. [read post]
24 Apr 2014, 9:59 pm
In this Hatch-Waxman litigation, the plaintiffs (patent owners and licensees) brought suit after the defendants filed an ANDA with a paragraph IV certification alleging that the claims of plaintiffs' patent 5,721,244 ("'244 patent") were obvious. [read post]
30 Jun 2015, 9:59 pm
It was evident that the presence of a large cash payment from the innovator (branded) drug company to the generic challenger as part of a "reverse payment" settlement agreement in ANDA litigation was enough to provoke a "rule of reason" antitrust analysis according to the rubrics set forth in Justice Breyer's opinion. [read post]
3 Sep 2012, 8:55 pm
Apotex Inc. 1:12-cv-01090; filed August 31, 2012 Infringement of U.S. [read post]
15 Apr 2009, 8:56 pm
., Barr Pharmaceuticals Inc., and Sandoz Inc. with respect to a generic version of Razadyne ® ER. [read post]
19 Nov 2012, 4:00 am
Last week, FDA denied a Citizen Petition filed by Jazz Pharmaceuticals, Inc ("Jazz"). [read post]
7 Jul 2020, 6:04 am
Apotex Inc., the defendants converted their Paragraph IV certifications for certain patents at issue to Paragraph III certifications. [read post]
15 Oct 2007, 9:14 pm
ANDA Filing Not Violation of Express Terms of Injunction By Sherri Oslick -- In an opinion authored by Chief Judge Michel and issued late last week, the CAFC reversed the United States District Court for the Northern District of Illinois, finding Apotex not to have violated an injunction prohibiting it... [read post]
